Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The pre-ASCT serum albumin and pre-ASCT dFLC are prognostic markers in renal light chain amyloidosis patients treated with autologous stem cell transplantation

Bone Marrow Transplantation volume 60, pages 888–890 (2025)Cite this article

Subjects

To The Editor

Autologous peripheral blood stem cell transplantation (ASCT) has been used as an important first-line or salvage treatment option for systemic light chain (AL) amyloidosis and leads to a hematologic complete response (CR) in 30–40% of patients, with a median overall survival (OS) exceeding 15 years for patients who achieved CR [1, 2]. Although many factors have been reported to predict OS in patients treated with ASCT [2, 3], to date, there is no validated staging system for stratifying these patients. Furthermore, the renal staging system discriminates less well between stage I and stage II patients who underwent ASCT [4]. Therefore, this study conducted a retrospective analysis to establish a staging system for predicting overall and renal survival in renal AL amyloidosis patients who were treated with ASCT.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Survival curves of patients and comparison with survival curves after appropriate grouping.

Data availability

The data are available from the corresponding author on reasonable request.

References

  1. D’Souza A, Dispenzieri A, Wirk B, Zhang M-J, Huang J, Gertz MA, et al. Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015;33:3741–9.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gustine JN, Staron A, Szalat RE, Mendelson LM, Joshi T, Ruberg FL, et al. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study. Am J Hematol. 2022;97:1189–99.

    Article  PubMed  Google Scholar 

  3. Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, et al. Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time. J Clin Oncol. 2018;36:1323–9.

    Article  PubMed  Google Scholar 

  4. Havasi A, Stern L, Lo S, Sun F, Sanchorawala V. Validation of new renal staging system in AL amyloidosis treated with high dose melphalan and stem cell transplantation. Am J Hematol. 2016;91:E458-60.

  5. Vaxman I, Sidiqi MH, Al Saleh AS, Kumar S, Muchtar E, Dispenzieri A, et al. Depth of response prior to autologous stem cell transplantation predicts survival in light chain amyloidosis. Bone Marrow Transplant. 2020;56:928–35.

    Article  PubMed  Google Scholar 

  6. Goodman HJB, Gillmore JD, Lachmann HJ, Wechalekar AD, Bradwell AR, Hawkins PN. Outcome of autologous stem cell transplantation for AL amyloidosis in the UK. Br J Haematol. 2006;134:417–25.

    Article  PubMed  Google Scholar 

  7. Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119:1117–22.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Sharpley FA, Petrie A, Mahmood S, Sachchithanantham S, Lachmann HJ, Gillmore JD, et al. A 24‐year experience of autologous stem cell transplantation for light chain amyloidosis patients in the United Kingdom. Br J Haematol. 2019;187:642–52.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported by grants from the National Natural Science Foundation of China (82270767) and the Key Research and Development Plan Project of Jiangsu Province - Social Development Projects (BE2023797). The authors thank all members of the National Clinical Research Center of Kidney Diseases, Jinling Hospital for caring for AL amyloidosis patients and helping to extract data. Above all, we are deeply grateful to patients and their caregivers for participating in this trial.

Author information

Author notes

  1. These authors contributed equally: Wencui Chen, Yuanyuan Zhang.

  2. These authors jointly supervised this work: Zhihong Liu, Xianghua Huang.

Authors and Affiliations

  1. National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

    Wencui Chen, Jinzhou Guo, Xiaomei Wu, Weiwei Xu, Zhihong Liu & Xianghua Huang

  2. Southeast University School of Medicine, Nanjing, China

    Yuanyuan Zhang

Authors
  1. Wencui Chen
    View author publications

    Search author on:PubMed Google Scholar

  2. Yuanyuan Zhang
    View author publications

    Search author on:PubMed Google Scholar

  3. Jinzhou Guo
    View author publications

    Search author on:PubMed Google Scholar

  4. Xiaomei Wu
    View author publications

    Search author on:PubMed Google Scholar

  5. Weiwei Xu
    View author publications

    Search author on:PubMed Google Scholar

  6. Zhihong Liu
    View author publications

    Search author on:PubMed Google Scholar

  7. Xianghua Huang
    View author publications

    Search author on:PubMed Google Scholar

Contributions

ZHL, XHH, WCC and YYZ designed the research and interpreted the data. WCC and YYZ collected data, analyzed the data and wrote the manuscript. JZG, XMW and WWX contributed to collecting data, managed patients and revised the manuscript critically. All authors reviewed the manuscript draft and approved the final version of the manuscript.

Corresponding authors

Correspondence to Zhihong Liu or Xianghua Huang.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The study was approved by ethics committees of Jinling hospital and was conducted according to the Declaration of Helsinki. All patients in this study have signed an informed consent form for the use of clinical data for research purposes.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chen, W., Zhang, Y., Guo, J. et al. The pre-ASCT serum albumin and pre-ASCT dFLC are prognostic markers in renal light chain amyloidosis patients treated with autologous stem cell transplantation. Bone Marrow Transplant 60, 888–890 (2025). https://doi.org/10.1038/s41409-025-02575-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-025-02575-5

Search

Advanced search

Quick links